Pheno

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Acceleration, Environment, International, Telephone, Security (finance), Table, Bruker, Cost, Investment, GAAP, Sensitivity and specificity, Pheno, FDA, Food

TUCSON, Ariz., March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • TUCSON, Ariz., March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
  • Net sales for the quarter were $3.0 million, compared to $3.0 million for the same quarter of the prior year.
  • Management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results.
  • To listen to the 2023 fourth quarter and full year results, call by phone, +1.877.883.0383 and enter Elite Entry Number: 7172610. International participants may dial +1.412.902.6506.

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Retrieved on: 
Wednesday, January 11, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Multiple sclerosis, Therapy, Degenerative disease, Pheno, Remyelination, UCB, Research, Pharmaceutical industry

The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.

Key Points: 
  • The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.
  • “Pheno Therapeutics utilized its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination.
  • This license allows us to accelerate a promising drug target towards clinical development,” said Fraser Murray, PhD., Chief Executive Officer of Pheno Therapeutics.
  • Pheno Therapeutics will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialization.

Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit

Retrieved on: 
Monday, December 19, 2022
Security (finance), Annual report, Patient, Acceleration, Pheno, Bloodstream infections, FDA, Gram, Laboratory, Sepsis, Acinetobacter baumannii, Publication, Multimedia, Risk, Hospital, Pharmaceutical industry

TUCSON, Ariz., Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit.

Key Points: 
  • TUCSON, Ariz., Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit.
  • Included in the submission are additional escalation and de-escalation agents for Gram-negative organisms, additional antibiotics for Acinetobacter baumannii, and breakpoint updates.
  • These updates add oral de-escalation antibiotic options for clinicians to use, which can assist with expediting patient discharge plans.
  • Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.